Ropsacitinib
Alternative Names: PF-06826647Latest Information Update: 28 Dec 2024
At a glance
- Originator Pfizer
- Developer Pfizer; Priovant Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Cyclobutanes; Nitriles; Pyrazines; Pyrazoles; Skin disorder therapies; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders
- Discontinued Hidradenitis suppurativa; Inflammatory bowel diseases; Plaque psoriasis; Ulcerative colitis; Unspecified
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for clinical-Phase-Unknown development in Immunological-disorders in Unknown (PO)
- 10 Jan 2022 Pfizer completes a phase-II trial in Hidradenitis suppurativa in Canada, Australia and USA (PO) (NCT04092452)
- 09 Dec 2021 Chemical structure information added